WANY
VKTX icon

Wealthspire Advisors (New York)’s Viking Therapeutics VKTX Stock Holding History

Wealthspire Advisors (New York)’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-110
Closed -$2.89K – 2841
2025
Q3 		$2.89K Buy
+110
New +$3.28K ﹤0.01% 2496

Other funds holding VKTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Wealthspire Advisors (New York)'s VKTX Position: Q4 2025 in Review

Wealthspire Advisors (New York) sold out of Viking Therapeutics (VKTX) in Q4 2025, closing a stake of 110 shares — an estimated $2.89K sold.

Wealthspire Advisors (New York) first reported a position in VKTX in Q3 2025 and held it in 1 quarter. The position peaked at $2.89K in Q3 2025. 427 funds tracked by Wall St. Rank hold VKTX as of Q4 2025.

  • Wealthspire Advisors (New York) reported no remaining Viking Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Wealthspire Advisors (New York) sold 110 Viking Therapeutics shares in Q4 2025, an estimated $2.89K.
  • Wealthspire Advisors (New York) first reported a position in Viking Therapeutics in Q3 2025 and held it in 1 quarter.
  • Wealthspire Advisors (New York)'s Viking Therapeutics position peaked at $2.89K in Q3 2025.
  • 427 funds tracked by Wall St. Rank held Viking Therapeutics as of Q4 2025.

Based on Wealthspire Advisors (New York)'s 13F filing for Q4 2025, filed 13 Feb 2026.